Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Droxidopa Clear all
Completed Not applicable Interventional

Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease

NCT03173781
View directory record Official record
Conditions
Parkinson's Disease
Interventions
droxidopa, Placebo
Drug
Lead sponsor
Colorado Springs Neurological Associates
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 20, 2026, 8:50 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

NCT00547911
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases
Interventions
Droxidopa, Carbidopa, Entacapone
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 2 Interventional Results available

Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension

NCT00657046
View directory record Official record
Conditions
Intradialytic Hypotension
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 20, 2026, 8:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease

NCT07398508
View directory record Official record
Conditions
Menkes Disease
Interventions
Droxidopa Oral Product, Placebo Control
Drug · Other
Lead sponsor
Stephen G. Kaler
Other
Eligibility
7 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 8:50 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease

NCT01331122
View directory record Official record
Conditions
Gait Disorders, Neurologic
Interventions
droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 20, 2026, 8:50 AM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT03567447
View directory record Official record
Conditions
Parkinson Disease, Falls Patient
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 20, 2026, 8:50 AM EDT
Terminated Phase 4 Interventional

A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease

NCT03034564
View directory record Official record
Conditions
Parkinson Disease, Fatigue, Parkinsonism
Interventions
Northera, Placebo Oral Tablet
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 20, 2026, 8:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist

NCT03070730
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance
Interventions
Droxidopa, Atenolol, Placebos
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 20, 2026, 8:50 AM EDT
Recruiting Phase 1 Interventional

Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

NCT02897063
View directory record Official record
Conditions
Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Orthostatic Hypotension
Interventions
Droxidopa, Midodrine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 4 Interventional Results available

Lundbeck TOMs Orthostatic Hypotension

NCT04510922
View directory record Official record
Conditions
Orthostatic Hypotension, Idiopathic Parkinson Disease
Interventions
Droxidopa 100 MG [Northera]
Drug
Lead sponsor
Alberto Espay, MD, MSc
Other
Eligibility
30 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

NCT00738062
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
44
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 20, 2026, 8:50 AM EDT
Recruiting Phase 2 Interventional

Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury

NCT06937307
View directory record Official record
Conditions
Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
Interventions
Droxidopa capsules, Placebo
Drug · Other
Lead sponsor
Giuseppe Cullaro, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 8:50 AM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

NCT02812147
View directory record Official record
Conditions
Parkinson Disease
Interventions
L-DOPS, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose

NCT01327066
View directory record Official record
Conditions
QTc Interval
Interventions
Droxidopa, Moxifloxacin, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 4 Interventional

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

NCT03229174
View directory record Official record
Conditions
Parkinson Disease, Neurogenic Orthostatic Hypotension
Interventions
Droxidopa, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 20, 2026, 8:50 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Multi-Center, Open-Label Study

NCT01468259
View directory record Official record
Conditions
Renal Disease, End Stage Renal Disease
Interventions
Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 20, 2026, 8:50 AM EDT
Terminated Phase 2 Interventional Results available

Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome

NCT00977171
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Orthostatic Hypotension, Neurally Mediated Hypotension, Neurogenic Orthostatic Hypotension
Interventions
Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 20, 2026, 8:50 AM EDT
Approved For Marketing No phase listed Expanded access

Long Term Treatment With L-DOPS

NCT00889135
View directory record Official record
Conditions
Dopamine Beta Hydroxylase (DBH) Deficiency
Interventions
droxidopa
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 20, 2026, 8:50 AM EDT
Recruiting No phase listed Observational

Autonomic Dysfunction in Patients Following Bariatric Surgery: The ADiPOSE Study

NCT06289413
View directory record Official record
Conditions
Autonomic Dysfunction, Orthostatic Intolerance
Interventions
Development of AD/OI after BS
Other
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Timeline
2024 – 2025
U.S. locations
8
States / cities
Overland Park, Kansas • Independence, Missouri • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

NCT00782340
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Placebo, Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome

NCT04977388
View directory record Official record
Conditions
Menkes Disease, Occipital Horn Syndrome
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Stephen G. Kaler, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 20, 2026, 8:50 AM EDT
Recruiting Phase 4 Interventional

Treatment of Orthostatic Hypotension in SCI

NCT05839652
View directory record Official record
Conditions
Hypotension
Interventions
Midodrine Hydrochloride
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 20, 2026, 8:50 AM EDT
Enrolling by invitation Phase 2 Interventional

Droxidopa / Pyridostigmine in Orthostatic Hypotension

NCT01370512
View directory record Official record
Conditions
Orthostatic Hypotension
Interventions
Droxidopa, Pyridostigmine, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 4 Interventional Results available

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

NCT03115827
View directory record Official record
Conditions
Parkinson Disease
Interventions
Droxidopa, Carbidopa
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 20, 2026, 8:50 AM EDT